SeaSpine commenced full commercial launch of the Regatta® minimally invasive lateral interbody fusion system featuring NanoMetalene® titanium surface technology.
The system’s lateral retractor and the electromyography nerve detection dilators allow customizable, minimally disruptive access through the psoas, while providing visualization to perform the procedure.
NanoMetalene, a sub-micron layer of titanium that is molecularly bonded to PEEK using atomic fusion deposition, is designed to provide a bone-friendly titanium surface on endplates and throughout graft openings while retaining the benefits associated with PEEK such as biocompatibility, elasticity similar to bone and radiographic visibility.
Regatta is expected to help SeaSpine more deeply penetrate in existing accounts while reaching new customers who perform less invasive interbody fusion procedures. The system addresses a gap in SeaSpine’s lateral product portfolio, and leadership expects it to attract higher quality distributors and be an important driver for revenue growth, starting in 2H19.
SeaSpine commenced full commercial launch of the Regatta® minimally invasive lateral interbody fusion system featuring NanoMetalene® titanium surface technology.
The system's lateral retractor and the electromyography nerve detection dilators allow customizable, minimally disruptive access through the psoas, while providing visualization to...
SeaSpine commenced full commercial launch of the Regatta® minimally invasive lateral interbody fusion system featuring NanoMetalene® titanium surface technology.
The system’s lateral retractor and the electromyography nerve detection dilators allow customizable, minimally disruptive access through the psoas, while providing visualization to perform the procedure.
NanoMetalene, a sub-micron layer of titanium that is molecularly bonded to PEEK using atomic fusion deposition, is designed to provide a bone-friendly titanium surface on endplates and throughout graft openings while retaining the benefits associated with PEEK such as biocompatibility, elasticity similar to bone and radiographic visibility.
Regatta is expected to help SeaSpine more deeply penetrate in existing accounts while reaching new customers who perform less invasive interbody fusion procedures. The system addresses a gap in SeaSpine’s lateral product portfolio, and leadership expects it to attract higher quality distributors and be an important driver for revenue growth, starting in 2H19.
Copy to clipboard 
